Shares of Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) traded up 3.7% on Friday . The company traded as high as $4.52 and last traded at $4.46, with a volume of 238,767 shares trading hands. The stock had previously closed at $4.30.

A number of analysts have weighed in on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Sunesis Pharmaceuticals in a research report on Monday, September 12th. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, September 13th. Cowen and Company restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Monday, September 12th. Finally, Wells Fargo & Co. upgraded shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, July 29th.

The firm’s market capitalization is $64.68 million. The stock’s 50-day moving average is $4.33 and its 200-day moving average is $3.53.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Friday, July 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.02. Sunesis Pharmaceuticals had a negative net margin of 1,503.34% and a negative return on equity of 806.43%. The business earned $0.60 million during the quarter, compared to the consensus estimate of $0.70 million. During the same period last year, the firm earned ($0.15) EPS. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, analysts forecast that Sunesis Pharmaceuticals Inc. will post ($2.65) EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Sunesis Pharmaceuticals by 0.9% in the second quarter. Vanguard Group Inc. now owns 2,499,581 shares of the biopharmaceutical company’s stock valued at $1,369,000 after buying an additional 21,209 shares during the period. First Eagle Investment Management LLC acquired a new stake in Sunesis Pharmaceuticals during the second quarter valued at about $822,000. Finally, BVF Inc. IL raised its stake in Sunesis Pharmaceuticals by 0.8% in the first quarter. BVF Inc. IL now owns 4,813,294 shares of the biopharmaceutical company’s stock valued at $2,599,000 after buying an additional 35,913 shares during the period. 49.32% of the stock is currently owned by institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

5 Day Chart for NASDAQ:SNSS

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.